LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Ferrell, W.R.; Kelso, E.B.; Lockhart, J.C.; Plevin, R.; McInnes, I.B. (2010)
Publisher: B M J Group
Languages: English
Types: Article
Subjects: QR180
Objective: Osteoarthritis is a global clinical challenge for which no effective disease-modifying agents currently exist. This study identified protease-activated receptor 2 (PAR-2) as a novel pathogenic mechanism and potential therapeutic target in osteoarthritis.\ud

\ud Methods: Experimental osteoarthritis was induced in wild-type and PAR-2-deficient mice by sectioning the medial meniscotibial ligament (MMTL), leading to the development of a mild arthropathy. Cartilage degradation and increased subchondral bone formation were assessed as indicators of osteoarthritis pathology.\ud

\ud Results: Four weeks following MMTL section, cartilage erosion and increased subchondral bone formation was evident in wild-type mice but was substantially reduced in PAR-2-deficient mice. Crucially, the therapeutic inhibition of PAR-2 in wild-type mice, using either a PAR-2 antagonist or a monoclonal antibody targeting the protease cleavage site of PAR-2, was also equally effective at reducing osteoarthritis progression in vivo. PAR-2 was upregulated in chondrocytes of wild-type but not sham-operated mice. Wild-type mice showed further joint degradation 8 weeks after the induction of osteoarthritis, but PAR-2-deficient mice were still protected.\ud

\ud Conclusions: The substantial protection from pathology afforded by PAR-2 deficiency following the induction of osteoarthritis provides proof of concept that PAR-2 plays a key role in osteoarthritis and suggests this receptor as a potential therapeutic target.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Brooks PM. The burden of musculoskeletal disease - a global perspective. Clin Rheumatol 2006;25:778-81.
    • 2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
    • 3. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-82.
    • 4. Xiang Y, Masuko-Hongo K, Sekine T, et al. Expression of proteinase-activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1beta, TNF-alpha and TGF-beta. Osteoarthr Cartil 2006;14:1163-73.
    • 5. Boileau C, Amiable N, Martel-Pelletier J, et al. Activation of proteinaseactivated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. Arthritis Res Ther 2007;9:R121.
    • 6. Ferrell WR, Lockhart JC, Kelso EB, et al. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 2003;111:35-41.
    • 7. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthr Cartil 2007;15:1061-9.
    • 8. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
    • 9. Kelso EB, Lockhart JC, Hembrough T, et al. Therapeutic promise of proteinaseactivated receptor-2 antagonism in joint inflammation. J Pharmacol Exp Ther 2006;316:1017-24.
    • 10. Hembrough T, Smith W, Laskowska D, et al. Anti-inflammatory antagonists of PAR-2 also have antitumor and antiangiogenic activity. Proc Am Assoc Cancer Res 2005;46:2610.
    • 11. Kelso EB, Ferrell WR, Lockhart JC, et al. Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist. Arthritis Rheum 2007;56:765-71.
    • 12. Daheshia M, Yao JQ. The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol 2008;35:2306-12.
    • 13. Smith R, Ransjรถ M, Tatarczuch L, et al. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation. J Bone Miner Res 2004;19:507-16.
    • 14. Qvist P, Bay-Jensen AC, Christiansen C, et al. The disease modifying osteoarthritis drug (DMOAD): is it in the horizon? Pharmacol Res 2008;58:1-7.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article